CG Oncology's cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer
Topline data show a recurrence-free survival hazard ratio of 0.32 with no Grade 3 or higher treatment-related adverse events, and the company is widening its planned BLA filings.
CG Oncology reported on 16 November 2026 that its Phase 3 PIVOT-006 trial met its primary endpoint. The study tested adjuvant intravesical cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle invasive bladder cancer (NMIBC) and in those with high-grade Ta disease.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): CG Oncology, Inc. ↗
Article written by VigiEye from the official source (CG Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.